Effectiveness of aprepitant in post‐acute COVID19 syndrome

This is the first case of a patient taking aprepitant for a post‐acute COVID‐19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome.

Detalles Bibliográficos
Autores principales: Reinoso‐Arija, Rocío, López‐Ramírez, Cecilia, Jimenez‐Ruiz, José Antonio, López‐Campos, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449093/
https://www.ncbi.nlm.nih.gov/pubmed/34567551
http://dx.doi.org/10.1002/ccr3.4646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449093/
https://www.ncbi.nlm.nih.gov/pubmed/34567551
http://dx.doi.org/10.1002/ccr3.4646

Ejemplares similares